Zim Laboratories Share Price

Zim Laboratories Limited was incorporated in February, 1984 under the name and style of Zim Laboratories Private Limited in Maharashtra. The Company became a Public Limited Company through fresh Certificate of Incorporation issued by the Registrar of Companies, Mumbai. The Company commenced its operations in 1989 and is a specialist firm focused on the developing, manufacturing, and global distribution of differentiated generic Pharmaceutical and Nutraceutical products in oral solid dosage forms. The Companys comprehensive services include both PreFormulation Intermediates (PFI) and Finished Formulations (FF) across numerous vital therapeutic areas globally.Companys core therapeutic focus areas include: Urology, Gastrointestinal, NSAIDs / Analgesics, Antiinfectives, Cardiovascular, Central Nervous System, and Vitamins Supplements. ZIM acts as a key supplier of both finished and semifinished products within its targeted markets. ZIM operates three stateoftheart manufacturing facilities i.e. General, Cephalosporin, and OTF and a wellestablished RD centre, all staffed by highly skilled professionals. During the year 201920, ZIM Health Technologies Limited was acquired, making it a wholly owned subsidiary of the Company. SIA ZIM Laboratories Limited got incorporated as a wholly owned subsidiary in Latvia.In 2023, the Company launched Thinoral (Patented Oral Thin Film technology) as an alternate drug delivery platform across RoW/Pharmerging Markets and EU. The Company entered into a joint venture with an Australian marketing company to launch New Innovative Products (NIP) and Oral Thin Films (OTF) in 2025. The OTF business marked a milestone with its first commercial order supplied in Europe for Sildenafil citrate 50 milligram ODS. The product was launched in Italy and Malta in 2025.During FY26, ZIM completed a total of 57 regulatory filings across key geographies, comprising 14 NIP filings, 29 OTF filings, and 14 FF filings. In line with the global expansion strategy, ZIM entered into strategic collaborations, including a partnership with a local UAE company to scale our Oral Thin Films (OTF) footprint across the GCC region during the year 2026.

For the full year FY2026–2027, revenue reached ₹385.78 crore and profit touched at ₹5.84 crore.